ARHGAP27P1-BPTFP1-KPNA2P3: A Potential Drug Target and Biomarker

Target Name: ARHGAP27P1-BPTFP1-KPNA2P3

NCBI ID: G109286553

ARHGAP27P1-BPTFP1-KPNA2P3

Other Name(s): ARHGAP27P1-BPTFP1-KPNA2P3 readthrough, transcribed pseudogene

ARHGAP27P1-BPTFP1-KPNA2P3: A Potential Drug Target and Biomarker

Introduction

ARHGAP27P1-BPTFP1-KPNA2P3 is a transcribed pseudogene that is located on chromosome 16q22. It has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The ARHGAP27P1 gene is a member of the Cao Cao family transcription factor (ARHGAP27P1) family, which plays important roles in many developmental and physiological processes. BPTFP1 and KPNA2P3 are the two coding regions of the ARHGAP27P1 gene. The proteins they encode are involved in the cell cycle and signal transduction processes respectively.

In recent years, more and more studies have found that the expression level of the ARHGAP27P1 gene changes in many diseases, and these changes may be related to the characteristics and development of the disease. In addition, some studies have also shown that the expression level of the ARHGAP27P1 gene is positively correlated with the expression level of certain biological specimens, including urine, feces, saliva, tears, etc.

Based on these studies, we can speculate that ARHGAP27P1-BPTFP1-KPNA2P3 may be a potential drug target or biomarker. By targeting this gene, many diseases related to this gene can be treated.

drug target

ARHGAP27P1-BPTFP1-KPNA2P3 is a gene that plays an important role in many biological processes. In cancer, the expression level of the ARHGAP27P1 gene often changes, which may be related to cancer progression and treatment response. For example, some studies have found that the expression level of the ARHGAP27P1 gene is positively correlated with the survival rate of breast cancer patients.

neurodegenerative diseases

Neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease, and Huntington's disease, are closely related to the dysfunction of the ARHGAP27P1 gene. More and more studies have shown that abnormal expression of the ARHGAP27P1 gene is closely related to the occurrence and development of neurodegenerative diseases.

kidney disease

Kidney disease is a common disease that is also related to dysfunction of the ARHGAP27P1 gene. Studies have shown that the expression level of the ARHGAP27P1 gene is related to changes in glomerular filtration rate, which is an important indicator of kidney disease.

Liver Disease

Liver disease is a common disease that is also related to dysfunction of the ARHGAP27P1 gene. Studies have shown that the expression level of the ARHGAP27P1 gene is related to the risk and severity of liver disease, a serious disease that can lead to serious health problems.

Biomarkers

Biomarkers are biological molecules that can be used to diagnose and monitor patients with a disease. Since ARHGAP27P1-BPTFP1-KPNA2P3 is a gene whose expression levels change in many diseases, it can be used as a potential biomarker.

Abnormal expression of ARHGAP27P1 gene is closely related to the occurrence and development of many diseases. By targeting the ARHGAP27P1 gene, many diseases related to this gene can be treated. Future research will continue to further investigate the function of the ARHGAP27P1-BPTFP1-KPNA2P3 gene to determine its potential in drug research and clinical applications.

Protein Name: ARHGAP27P1-BPTFP1-KPNA2P3 Readthrough, Transcribed Pseudogene

The "ARHGAP27P1-BPTFP1-KPNA2P3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARHGAP27P1-BPTFP1-KPNA2P3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets